These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21142079)

  • 1. Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness.
    Oashi T; Ringer AL; Raman EP; Mackerell AD
    J Chem Inf Model; 2011 Jan; 51(1):148-58. PubMed ID: 21142079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Property distribution of drug-related chemical databases.
    Oprea TI
    J Comput Aided Mol Des; 2000 Mar; 14(3):251-64. PubMed ID: 10756480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug- and lead-likeness, target class, and molecular diversity analysis of 7.9 million commercially available organic compounds provided by 29 suppliers.
    Chuprina A; Lukin O; Demoiseaux R; Buzko A; Shivanyuk A
    J Chem Inf Model; 2010 Apr; 50(4):470-9. PubMed ID: 20297844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay.
    Yu WM; Guvench O; Mackerell AD; Qu CK
    J Med Chem; 2008 Dec; 51(23):7396-404. PubMed ID: 19007293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple approach for indexing the oral druglikeness of a compound: discriminating druglike compounds from nondruglike ones.
    Biswas D; Roy S; Sen S
    J Chem Inf Model; 2006; 46(3):1394-401. PubMed ID: 16711759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of physiochemical property profiles of development and marketed oral drugs.
    Wenlock MC; Austin RP; Barton P; Davis AM; Leeson PD
    J Med Chem; 2003 Mar; 46(7):1250-6. PubMed ID: 12646035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A large descriptor set and a probabilistic kernel-based classifier significantly improve druglikeness classification.
    Li Q; Bender A; Pei J; Lai L
    J Chem Inf Model; 2007; 47(5):1776-86. PubMed ID: 17718552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond.
    Odi R; Bibi D; Wager T; Bialer M
    Epilepsia; 2020 Aug; 61(8):1543-1552. PubMed ID: 32614073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.
    Wager TT; Hou X; Verhoest PR; Villalobos A
    ACS Chem Neurosci; 2010 Jun; 1(6):435-49. PubMed ID: 22778837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Drug-likeness Rules Apply to Oral Prodrugs?
    Protti ÍF; Rodrigues DR; Fonseca SK; Alves RJ; de Oliveira RB; Maltarollo VG
    ChemMedChem; 2021 May; 16(9):1446-1456. PubMed ID: 33471444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR model for drug human oral bioavailability.
    Yoshida F; Topliss JG
    J Med Chem; 2000 Jun; 43(13):2575-85. PubMed ID: 10891117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.
    Margolskee A; Darwich AS; Pepin X; Pathak SM; Bolger MB; Aarons L; Rostami-Hodjegan A; Angstenberger J; Graf F; Laplanche L; Müller T; Carlert S; Daga P; Murphy D; Tannergren C; Yasin M; Greschat-Schade S; Mück W; Muenster U; van der Mey D; Frank KJ; Lloyd R; Adriaenssen L; Bevernage J; De Zwart L; Swerts D; Tistaert C; Van Den Bergh A; Van Peer A; Beato S; Nguyen-Trung AT; Bennett J; McAllister M; Wong M; Zane P; Ollier C; Vicat P; Kolhmann M; Marker A; Brun P; Mazuir F; Beilles S; Venczel M; Boulenc X; Loos P; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():598-609. PubMed ID: 27671970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.
    Yu ZH; Chen L; Wu L; Liu S; Wang L; Zhang ZY
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4238-42. PubMed ID: 21669525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting oral druglikeness by iterative stochastic elimination.
    Rayan A; Marcus D; Goldblum A
    J Chem Inf Model; 2010 Mar; 50(3):437-45. PubMed ID: 20170135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery.
    Fink T; Reymond JL
    J Chem Inf Model; 2007; 47(2):342-53. PubMed ID: 17260980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors.
    Matter H
    J Med Chem; 1997 Apr; 40(8):1219-29. PubMed ID: 9111296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
    Liu WS; Yang B; Wang RR; Li WY; Ma YC; Zhou L; Du S; Ma Y; Wang RL
    Bioorg Chem; 2020 Jul; 100():103875. PubMed ID: 32380342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
    Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.